24 Apr, 2026
Feel free to reach out to us.
24 Apr, 2026
Liquid biopsy for cancer analyzes tumor-derived DNA that cancer cells release into the bloodstream during normal cell turnover. With a single blood draw, oncologists can build a detailed molecular profile of a tumor, information that previously required surgical biopsy and weeks of laboratory processing. No incision, no recovery period, and no additional burden on a patient already managing a difficult diagnosis.
What makes this procedure significant is not just the convenience. Cancer hospitals across India are using liquid biopsy today for personalized treatment planning, monitoring therapeutic response, and identifying relapse earlier than conventional imaging allows.
In this article, we learn about the key aspects of liquid biopsy.
Every time a tumor cell divides or breaks down, it releases short DNA fragments into the surrounding bloodstream. These fragments carry the genetic signature of the tumor itself. Liquid biopsy captures those fragments from a plasma sample. Then Next-Generation Sequencing (NGS) decodes them, identifying single-nucleotide variants, copy number changes, gene fusions, tumor mutation burden (TMB), and microsatellite instability (MSI) all at once.
In early-stage cancers, ctDNA concentrations in blood are small. Detection sensitivity improves as disease burden grows. Serial testing over time often reveals more than a single snapshot ever could.
People can easily confuse liquid biopsy with tissue biopsy. Here’s how they are different:
| Parameter | Tissue Biopsy | Liquid Biopsy |
|---|---|---|
| Invasiveness | Surgical or needle procedure | Routine blood draw |
| Tumor view | Single-site snapshot | Whole-body molecular signal |
| Repeat feasibility | Rarely practical | Simple serial draws |
| Result timeline | Days to weeks | 5 to 10 business days |
| Primary clinical role | Initial diagnosis, histology | Monitoring, MRD, resistance |
| Procedural risk | Bleeding, infection, sedation | Venipuncture only |
Liquid biopsy cannot confirm a brand-new cancer diagnosis on its own. Pathological tissue review is still the definitive first step. The value of liquid biopsy emerges after that: tracking, monitoring, and adjusting.
Accuracy depends on how much ctDNA is circulating, and that number is directly tied to how active the disease is. In later-stage cancers, sensitivity is clinically stronger than for early-stage cancers. Modern signal enrichment technology and refined sequencing chemistry are shrinking that gap year by year.
Liquid biopsy is most powerful as a treatment-monitoring and resistance-detection tool. Its role in pure early screening is growing fast, but your oncologist will guide where it fits best in your specific care plan.
Validated clinical use spans lung, colorectal, breast, ovarian, pancreatic, and blood cancers. At HCG, oncologists apply liquid biopsy to guide targeted treatment decisions across the following:
Your oncologist selects the gene panel based on your specific cancer subtype and treatment stage. There is no universal panel. The choice is always personalized.
At HCG, liquid biopsy results are reviewed by a dedicated molecular diagnostics team — bioinformatics specialists and senior oncologists who interpret findings together before treatment decisions are made. The process is structured to ensure that a molecular result translates into a clinically actionable plan, not just a data point.
The process, step by step:
Minimal Residual Disease (MRD) testing detects ctDNA that lingers in the blood after chemotherapy or surgery. A patient can have a clean scan and still carry a microscopic disease that imaging simply cannot resolve. Persistently detectable ctDNA after treatment tells the oncologist that adjuvant therapy deserves serious consideration. Undetectable ctDNA, paired with clear imaging, provides the most complete reassurance currently available.
In summary, MRD through liquid biopsy gives clinicians a molecular second opinion that no radiological scan can replicate.
At HCG, liquid biopsy testing costs range from approximately ₹25,000 to ₹2,80,000, depending on the panel selected. Targeted panels start at the lower end of that range. Mid-range panels, including the 56-gene and 76-gene options, fall between ₹60,000 and ₹1,75,000. Comprehensive 500-gene NGS panels occupy the higher bracket. Your oncologist will recommend the appropriate panel based on your cancer type and treatment stage.
Liquid biopsy costs vary by hospital and patient profile. Insurance coverage is expanding but inconsistent across payers. Verify pre-authorization with your insurer before confirming any appointment.
In cancer care, the difference between information and insight comes down to what happens after a result is reported. At HCG, liquid biopsy findings are reviewed by a dedicated molecular diagnostics team, bioinformatics specialists, and senior oncologists who assess each result in clinical context before any treatment adjustment is made. Where a tumor is located tells part of the story. How it behaves genetically, and how that behavior shifts over time, increasingly tells the rest.
For patients who are mid-treatment or approaching the end of a therapy course, a conversation with your oncologist about ctDNA monitoring is worth having. What shows up, or does not show up, in that blood draw can influence what your care plan looks like next.
Next Steps for Your Doctor Visit:
Disclaimer: This information is intended to educate patients and caregivers. It does not replace professional medical advice. All treatment decisions should be made in consultation with a qualified doctor.
